Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Lapatinib

Nature Reviews Drug Discovery volume 6, pages 431–432 (2007)Cite this article

Abstract

Lapatinib

Lapatinib is a small-molecule kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2). In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Lapatinib.

References

  1. Nahta, R. et al. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8, 5–17 (2003).

    Article  CAS  Google Scholar 

  2. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification ofthe HER-2/neu oncogene. Science 235, 177–182 (1987).

    Article  CAS  Google Scholar 

  3. Valabrega, G. et al. Trastuzumab: mechanism of action, resistance, and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 17 Jan 2007 (doi:10.1093/annonc/mdl475).

    Article  CAS  Google Scholar 

  4. Jackisch, C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 11 (Suppl. 1), 34–41 (2006).

    Article  CAS  Google Scholar 

  5. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).

    Article  CAS  Google Scholar 

  6. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-postive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).

    Article  CAS  Google Scholar 

  7. Moy, B. & Goss, P. E. Lapatinib: current status and future directions in breast cancer. Oncologist 11, 1047–1057 (2006).

    Article  CAS  Google Scholar 

  8. Rusnak, D. W. et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85–94 (2001).

    CAS  PubMed  Google Scholar 

  9. Food and Drug Administration. FDA labelling information [online], (2007).

  10. Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630–1639 (2006).

    Article  CAS  Google Scholar 

  11. Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).

    Article  CAS  Google Scholar 

  12. Clayton, A. J. et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer. 91, 639–643 (2004).

    Article  CAS  Google Scholar 

  13. Guarneri, V. et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J. Clin. Oncol. 24, 4107–4115 (2006).

    Article  CAS  Google Scholar 

  14. Perez, E. A. et al. Cardiac safety experience in 3127 patients treated with lapatinib. Ann. Oncol. 17 (Suppl. 9), A1420 (2006).

    Google Scholar 

  15. MS Health, IMS MIDAS Quantum (2006).

Download references

Author information

Authors and Affiliations

  1. Beverly Moy and Paul Goss are at the Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA. bmoy@partners.org pgoss@partners.org,

    Beverly Moy & Paul Goss

  2. Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. skar@uk.imshealth.com,

    Santwana Kar

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Beverly Moy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Santwana Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Beverly Moy has served as a consultant to Genentech and GlaxoSmithKline. Paul Goss declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moy, B., Kirkpatrick, P., Kar, S. et al. Lapatinib. Nat Rev Drug Discov 6, 431–432 (2007). https://doi.org/10.1038/nrd2332

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2332

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing